Stockscreener 앱 받기
17.53
1.74%
-0.31
시장 영업 전:
16.85
-0.68
-3.88%
전일 마감가:
$17.84
열려 있는:
$17.69
하루 거래량:
2.68M
Relative Volume:
0.96
시가총액:
$2.22B
수익:
$631.73M
순이익/손실:
$-239.78M
주가수익비율:
-8.6782
EPS:
-2.02
순현금흐름:
$-33.45M
1주 성능:
-1.90%
1개월 성능:
+2.63%
6개월 성능:
+64.60%
1년 성능:
+8.54%
1일 변동 폭
$17.41
$18.38
1주일 범위
$17.06
$18.38
52주 변동 폭
$6.78
$20.34
10X 제노믹스 Stock (TXG) Company Profile
명칭
10 X Genomics Inc
전화
(925) 401-7300
주소
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
TXG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
17.53 | 2.26B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
229.16 | 38.14B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
75.07 | 13.50B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
45.04 | 8.50B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
95.73 | 7.97B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
35.20 | 6.39B | 11.99B | 24.18M | 234.31M | 0.2956 |
10X 제노믹스 Stock (TXG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | 개시 | Piper Sandler | Neutral |
| 2025-02-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | 개시 | Leerink Partners | Outperform |
| 2024-07-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-07-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-10 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-06-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-05-01 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-10 | 개시 | Barclays | Overweight |
| 2023-03-31 | 개시 | Stephens | Overweight |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-08-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-07-25 | 개시 | Canaccord Genuity | Buy |
| 2022-07-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-09-14 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-15 | 개시 | William Blair | Outperform |
| 2020-12-02 | 개시 | Goldman | Neutral |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-07-10 | 개시 | Stifel | Buy |
| 2020-03-05 | 개시 | Guggenheim | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-07 | 개시 | BofA/Merrill | Buy |
| 2019-10-07 | 개시 | Cowen | Outperform |
| 2019-10-07 | 개시 | JP Morgan | Overweight |
| 2019-09-24 | 개시 | Evercore ISI | Outperform |
모두보기
10X 제노믹스 주식(TXG)의 최신 뉴스
10x Genomics $TXG Shares Bought by Jump Financial LLC - MarketBeat
Life Sciences Tools & Services Stocks Q3 Earnings: 10x Genomics (NASDAQ:TXG) Firing on All Cylinders - Finviz
Why 10x Genomics Inc. stock appeals to analystsMarket Risk Summary & Long-Term Capital Growth Ideas - Newser
Russell Investments Group Ltd. Increases Stock Position in 10x Genomics $TXG - MarketBeat
Is 10x Genomics Inc. (1KJ) stock among top earnings playsJuly 2025 Highlights & Low Risk Entry Point Tips - Newser
Market Fear: Is CPSR stock trading at a premium valuation2025 Performance Recap & Fast Moving Stock Trade Plans - BỘ NỘI VỤ
10x Genomics Comments on Second UPC Preliminary Injunction Decis - GuruFocus
TXG: Morgan Stanley Downgrades 10x Genomics, Raises Price Target - GuruFocus
Tumor Transcriptomics Research Report 2025: An $8.71 Billion Market by 2030, Driven by Rising Global Cancer Prevalence and Advancements in Genomic Sequencing Technologies - GlobeNewswire Inc.
TXG Technical Analysis & Signals — Is 10x Genomics, Inc. Stock a Buy or Sell? - Meyka
Is 10x Genomics Inc. stock safe for conservative investors2025 Breakouts & Breakdowns & Weekly Return Optimization Alerts - BỘ NỘI VỤ
Aug Levels: Why 10x Genomics Inc. stock could benefit from AI revolutionJuly 2025 Institutional & Verified Technical Trade Signals - BỘ NỘI VỤ
What sentiment indicators say about 10x Genomics Inc. stockQuarterly Profit Summary & Reliable Breakout Forecasts - BỘ NỘI VỤ
10x Genomics to Acquire Scale Biosciences (PR Newswire) - Aktiellt
Buy Signal: Is 10x Genomics Inc. stock safe for conservative investorsWeekly Earnings Recap & Reliable Momentum Entry Alerts - BỘ NỘI VỤ
How 10x Genomics Inc. stock responds to policy changes2025 Volatility Report & Risk Managed Trade Strategies - BỘ NỘI VỤ
10x Genomics Insider Sold Shares Worth $251,936, According to a Recent SEC Filing - marketscreener.com
[Form 4] 10x Genomics, Inc. Insider Trading Activity - Stock Titan
Pres Hindson Surrenders 8,283 Of 10X Genomics Inc [TXG] - TradingView
BrightSpring Health Services, 10x Genomics, QuidelOrtho, Medpace, and Fortrea Shares Are Soaring, What You Need To Know - Finviz
CEO Saxonov Files To Sell 13,096 Of 10X Genomics Inc [TXG] - TradingView
CFO Taich Files To Sell 11,312 Of 10X Genomics Inc [TXG] - TradingView
Q3 2025 10X Genomics Inc Earnings Call Transcript - GuruFocus
10x Genomics, Inc. (NASDAQ:TXG) Q4 2024 Earnings Call Transcript - MSN
10x Genomics, Inc.Common Stock (NQ: TXG - Markets Financial Content
Is 10x Genomics’ (TXG) New Asia-Pacific Consortium Key to Sustaining Its Leadership in Spatial Genomics? - Yahoo Finance
10x Genomics (TXG) Price Target Increased by 10.47% to 16.66 - MSN
Bruker, 10x Genomics, PacBio, ICU Medical, and Dentsply Sirona Shares Skyrocket, What You Need To Know - Yahoo Finance
10X Genomics stock hits 52-week high at 17.7 USD By Investing.com - Investing.com India
10X Genomics stock hits 52-week high at 17.7 USD - Investing.com
Spatial Biology Market Analysis and Forecast, 2025-2035: - GlobeNewswire
Spatial Biology Market Analysis and Forecast, 2025-2035: Stellaromics, RareCyte, and 10x Genomics Drive Innovation and Funding Momentum - Yahoo Finance
How 10x Genomics Inc. (1KJ) stock trades pre earnings2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
Total liabilities & shareholders' equities of 10x Genomics Inc Class A – HAM:1KJ - TradingView
Is 10x Genomics Inc. stock a buy before product launchesJuly 2025 Closing Moves & Safe Entry Zone Tips - newser.com
New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium - StreetInsider
3 Reasons to Avoid TXG and 1 Stock to Buy Instead - Yahoo Finance
10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch - MSN
TXG (10x Genomics) Inventory-to-Revenue : 0.44 (As of Sep. 2025) - GuruFocus
10x Genomics Announces Chief Legal Officer Retirement - The Globe and Mail
10x Genomics GC Who Led Rule Of Law Effort To Retire In '26 - Law360
There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump - simplywall.st
10x Genomics, Inc. Announces Executive Changes, Effective January 1, 2026 - MarketScreener
10X Genomics Stock Soars 17.31%, Hits Intraday High of $15.26 - Markets Mojo
10x Genomics Inc Class A Earnings and Revenue – HAM:1KJ - TradingView
How 10x Genomics Inc. (1KJ) stock valuation compares with sectorChart Signals & Safe Entry Point Alerts - newser.com
Why 10x Genomics Inc. (1KJ) stock attracts wealthy investorsSell Signal & Verified Stock Trade Ideas - newser.com
10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025 - Eastern Progress
TXG announces CLO retirement; Randy Wu to serve as General Counsel - Stock Titan
10x Genomics, Inc. (TXG) Stock Price Quote Today & Current Price Chart - Capital.com
10x Genomics (TXG): Assessing Valuation After Strong Earnings, Upbeat Forecast and New Product Launch - Yahoo Finance
10X 제노믹스 (TXG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.47%
0.10%
자본화:
|
볼륨(24시간):